Yersinia pestis is a category A pathogen and a potential agent of bioterrorism and biological warfare (6, 8) . This gram-negative bacterium causes bubonic, septicemic, or pneumonic plague and has killed millions of people during the three major pandemics in history. Even today, at least 2,000 cases of plague are reported annually to the World Health Organization (WHO). Furthermore, the identification of natural antibioticresistant strains emphasizes that the development of an effective vaccine is one of the urgent needs in the prevention of Y. pestis infections (15, 16) .
The great efforts in many laboratories have made promising progress in the development of vaccines against both bubonic and pneumonic plague (7, 20, 41) . Until now, most of these studies have focused largely upon antibody-based humoral immunity. However, results from vaccine trials with nonhuman primates suggest that humoral immunity may not suffice to protect humans against Y. pestis infection. Several studies of animal models have confirmed the roles of CD4 ϩ T helper 1 (Th1) cells and the cytokines gamma interferon (IFN-␥) and tumor necrosis factor alpha in plague protection (24, 32, 34, 40) . Cellular and humoral immune responses will synergize in combating plague infection. Ideally, plague vaccines should elicit both cellular and humoral immunity.
The subunit vaccines based on F1 (the fraction 1 capsule-like antigen) and/or V (LcrV) antigen proved to be efficient in small animals under laboratory conditions, and both of them can induce antibody responses with high titers (38, 47) . However, there is no a priori reason to assume that F1 and/or V constitutes the immunodominant target for the T-cell response, although previous findings indicate that Y. pestis must possess antigenic targets for cellular immunity (34) . Thus, to effectively incorporate cellular immunity into plague subunit vaccines, it is now imperative to define the specific Y. pestis proteins that elicit cellular immune responses.
The availability of complete bacterial genome sequences makes a push for reverse vaccinology to be put into practice (29, 31) . The development of protein microarrays and immunoproteomics let us identify novel immunogens that induce humoral immune responses in a high-throughput manner (1, 12, 19, 21, 27, 28) . The approach to identify T-cell antigens on a large scale is under way (10, 14) .
In this report, we describe the use of in silico computerbased analysis in combination with an in vitro IFN-␥ assay to identify potential T-cell antigens from Y. pestis by a highthroughput approach. In total, 34 individual proteins that stimulated strong IFN-␥ responses in splenocytes from mice immunized with Y. pestis live vaccine EV76 were identified. Nine of them can provide partial protection against challenge with 20 times the 50% lethal dose (20ϫ LD 50 ) of Y. pestis.
MATERIALS AND METHODS
In silico analysis and selection of candidate genes. First, all putative open reading frames (ORFs) in the Y. pestis CO92 strain (33) , the first sequenced strain of Y. pestis, were subjected to computer analysis to identify genes potentially encoding surface-exposed, membrane-associated proteins by using PSORTb (http://www.psort.org/psortb/), SignalP (http://www.cbs.dtu.dk/services/SignalP/), and ProtcompB (http://linux1.softberry.com/berry.phtml?topicϭpcompb&group ϭprograms&subgroupϭproloc) software. Next, the transmembrane domains in the products of the selected ORFs were analyzed by TopPred (http://mobyle .pasteur.fr/cgi-bin/MobylePortal/portal.py?formϭtoppred). The ORFs encoding proteins with more than three transmembrane domains were discarded. The genes that were likely to have been acquired in the evolution of Y. pestis, the ones encoding proteins homologous to protective antigens from other bacteria and the ones that may contribute to the virulence of Y. pestis according to currently available data, were then selected to be expressed in Escherichia coli.
Cloning, expression, and purification of His-tagged recombinant proteins. The selected ORFs were amplified by PCR from DNA of Y. pestis strain 82013, a fully virulent strain of biovar Orientalis isolated from Focus F (Rattus flavipectus plague focus of the Yunnan-Guangdong-Fujian provinces) in China, which was used as an alternative to strain CO92 in our laboratory. The amplified DNA fragments were cloned into the pDEST17 vector by using Gateway cloning technology or into the pET32a vector by using restriction enzyme digestion, and the encoded proteins were expressed in E. coli BL21(DE3) as N-terminally His-tagged fusion proteins. The expression of the recombinant proteins was evaluated according to the appearance of bands in the sodium dodecyl sulfatepolyacrylamide gel electrophoresis (SDS-PAGE) analyses. The recombinant fusion proteins were then purified by affinity chromatography on Ni 2ϩ -conjugated chelating Sepharose. Proteins expressed as inclusion bodies were solubilized with urea and refolded by dilution after purification. All the purified proteins were finally solubilized in phosphate-buffered saline (PBS)-1% glycine (0.01 M; pH 8.0). The purity of the purified proteins was ascertained by SDS-PAGE, and the concentrations were measured by using the bicinchoninic acid protein assay kit (Pierce). Potential endotoxin contamination was assessed for 30% of the proteins by using ATCC Pyrochrome chromogenic endotoxin testing reagents.
Immunization of mice with Y. pestis live vaccine EV76 and collection of splenocytes. Live, attenuated vaccine EV76 was obtained from the Lanzhou Institute of Biological Products, China. After cultivation at 26°C in Luria-Bertani broth to logarithmic phase, the cells were pelleted and washed twice with PBS (0.01 M; pH 7.2). Groups of six 6-to 8-week-old BALB/c mice were immunized intramuscularly with 5 ϫ 10 6 CFU of Y. pestis EV76 or 100 l of PBS as a control. Twenty-eight days later, the sera were collected for determining the titers of antibody against F1 antigen by enzyme-linked immunosorbent assay. On the 35th day, the immunized mice and nonimmunized control mice were killed humanely and the spleens were collected.
The splenocytes were harvested by passage of the spleens through 200-mesh copper net, and the cells from three mice in each group were pooled. The red cells were lysed by lysing buffer (BD Biosciences), and the splenocytes were washed three times with complete RPMI 1640 medium. The final pellet of splenocytes was suspended in complete RPMI 1640 medium at 5 ϫ 10 6 cells per ml. Enzyme-linked immunospot (ELISPOT) assay for IFN-␥-secreting cells. The splenocytes from immunized or nonimmunized control mice were plated at a density of 5 ϫ 10 5 cells per well into 96-well plates that had been coated with anti-IFN-␥ monoclonal antibody (clone R4-6A2; BD Pharmingen). The cells were stimulated with each of the purified recombinant proteins (10 g/ml), concanavalin A (ConA; 5 g/ml), or complete medium (RPMI 1640 medium) in triplicate. After incubation at 37°C in 5% CO 2 for 20 h, the plates were washed twice with deionized H 2 O and then three times with PBS-Tween 20 (0.05%). The plates were then incubated with biotinylated anti-mouse IFN-␥ antibody (clone XMG1.2; BD Pharmingen) for 2 h at room temperature. Plates were washed three times with PBS-Tween 20 and incubated with avidin-bound biotinylated horseradish peroxidase. After the plates were washed four times with PBSTween 20 and twice with PBS, the spots were visualized using the horseradish peroxidase substrate 3-amino-9-ethylcarbazole (BD Biosciences) and were counted using a cytotoxic-T-lymphocyte immunospot analyzer.
Immunization and protection experiments. To examine the protective efficiencies of recombinant proteins, adult BALB/c mice (6-to 8-week-old females; five per group) were immunized on days 1, 21, and 35 by intramuscular injection with 15 g of each protein mixed with 10 g of CpG1826 (5Ј-TCCATGACGT TCCTGACGTT-3Ј)-oligodeoxynucleotide (ODN) as an adjuvant. Two other groups of mice were injected with 10 g of CpG1826-ODN or 100 l of PBS alone as a negative or blank control. Mice were immunized with 15 g of LcrV antigen mixed with 10 g of CpG1826-ODN as a positive control.
On day 60 after the primary immunization, mice were subcutaneously challenged with 20ϫ LD 50 or 200ϫ LD 50 of the Y. pestis 201 strain per mouse. Y. pestis 201 is an alternative to strain 91001, a strain avirulent to humans, but is highly lethal to mice (the LD 50 is about 6 CFU for BALB/c mice) and was isolated from the rodent Brandt's vole (Microtus brandti) (43) . Mice were observed for 15 days postchallenge to determine the protection efficacy.
RESULTS AND DISCUSSIONS
Selection, expression, and purification of Y. pestis proteins. The subcellular localization of the products of 4,016 ORFs on the chromosome of the Y. pestis CO92 strain was analyzed in silico by using PSORTb, SignalP, and ProtcompB software, and the ORFs that potentially encode surface-exposed, membrane-associated proteins were identified. Because the proteins with multihydrophobic transmembrane domains had high rates of expression failure, proteins with more than three transmembrane domains, as determined by TopPred software, were discarded. Finally, 190 proven or putative pathogenesis-associated factors disclosed by signature tag mutagenesis, proteomics, comparative genomics, or gene expression profile analysis and proteins homologous to previously characterized protective antigens from other bacteria (9, 17, 26, 42) were selected. Thirty-eight lipoproteins and 33 putative or proven virulence factors encoded by the three plasmids of Y. pestis were also included. Finally, a total of 261 proteins were selected for further study (see Table S1 in the supplemental material).
By means of PCR, the amplified DNA sequences of the ORFs for these proteins were cloned into E. coli to express the recombinant fusion proteins with His tags. All proteins were cloned without putative signal sequences, and the proteins predicated to be larger than 60 kDa were expressed in smaller subfragments. According to the SDS-PAGE analysis, 174 ORFs (67%) were successfully expressed. As most of the proteins were membrane associated, 124 (71.3%) of them were expressed as inclusion bodies. All the proteins were purified by nickel-chelating chromatography, and the proteins expressed as inclusion bodies were refolded by a dilution strategy. The concentrations and purities of the purified proteins were evaluated by using the bicinchoninic acid assay kit (Pierce) and SDS-PAGE, respectively. The proteins whose purity was less than 85% were discarded. In the end, only 101 proteins were successfully purified and qualified for analysis of their abilities to stimulate T-cell responses in vitro (see Table  S1 in the supplemental material). The levels of endotoxin in a random selection of 30% of the samples of the above-mentioned proteins were measured by a Limulus amoebocyte lysate test and shown to be less than 0.06 endotoxin units/g (0.05 endotoxin units/g for YPO0606).
Proteins that induced immunodominant T-cell responses in mice immunized with EV76. To assess the T-cell reactivities of the Y. pestis proteins, BALB/c mice were intramuscularly injected with Y. pestis live vaccine EV76. This single-dose immunization can protect against high challenge doses (5.75 ϫ 10 6 minimal lethal doses) of virulent strain GB in a murine model (37) , and this live, attenuated vaccine is also able to protect animals against Y. pestis intranasal challenge. On the 28th day after immunization, the log 10 titer of antibody to F1 protein, the capsule antigen of Y. pestis, in the mouse sera was 3.9 Ϯ 0.14 (mean Ϯ standard error of the mean), suggesting that the single injection can induce strong immune responses in mice. (3, 5, 30, 44) . Based on the in silico analysis and previous research results, 23 proteins in the T3SS were selected for evaluation of their abilities to induce T-cell responses (see Table S1 in the supplemental material). Six of them (SycE, YopK, YopM, YopD, YscF, and LcrV) can induce strong T-cell responses in mice immunized with EV76. Except for YscF, these proteins have already been defined as major T-cell antigens and are recognized by human cytolytic T cells (39) .
Although the T-cell responses to LcrV were studied previously, this is the first demonstration that live plague vaccines can prime for LcrV-specific production of IFN-␥. YscF is a small, surface-exposed protein that polymerizes to form the external needle of the T3SS. Immunization of mice with the protein results in high-titer specific antibody which can provide protection against intravenous challenge with Y. pestis (30) . The production of IFN-␥ specific to YscF suggests that T-cellmediated immunity likely plays roles in the protection provided by YscF. In addition to the pCD1 plasmid, Y. pestis has acquired two unique plasmids, pMT1 and pPCP1, over the course of evolution from Yersinia pseudotuberculosis. The known virulence-associated factors capsule antigen F1 (YPMT1.84), Yersinia murine toxin (YPMT1.74), and plasminogen activator (YPPCP1.07) are encoded by these plasmids. Eight genes on these plasmids were selected to be expressed in E. coli, but only the proteins F1, Pla, and YPMT1.06c were successfully purified. None of them can induce strong T-cell responses in mice immunized with EV76.
Genes for the other 28 proteins which induced strong T-cell immunity were located on the chromosome. Antibody responses to five of these proteins (YPO1303, YPO1435, YPO2109, YPO3015, and YPO3382) have also been detected previously in infected animals and/or plague patients (27, 28) (Table 1) .
There are several reasons why some proteins were not recognized as T-cell immunogens in this research. First, the proteins in our study were recombinant, not native, so they had lost the posttranslational modifications present in the native proteins. Second, some of the proteins, such as YopH, were expressed only as portions of the full-length proteins; a previous study demonstrated that the fragment of YopH from amino acid 2 to 129, but not the fragment from amino acid 164 to 468, is recognized as a T-cell antigen (39) . The fragment expressed in the present study, from amino acid 31 to 231, did not stimulate the strong T-cell response, suggesting that the fragment from amino acid 2 to 31 may be the major T-cell epitope of YopH. Third, the optimal concentration for in vitro stimulation may be different for different proteins. However, in our study, we used the same concentration (10 g/ml) of each protein for an easy high-throughput operation. Although this study may ignore some proteins which also induce T-cell responses, it is the first to identify the novel T-cell antigens of Y. pestis by a high-throughput approach, and the proteins inducing stronger IFN-␥ responses would be the focus to help in the development of an effective vaccine for plague.
Protective efficiencies of the proteins against Y. pestis strain 122 in a mouse model. Of the 34 proteins which stimulated strong T-cell responses in mice immunized with EV76, YopM, YopK, YopD, LcrV, YscF, YPO1303, and YPO3015 have been determined to be protective in previous studies (5, 23, 27, 30, 45) . LcrV, YopD, and YscF have been proved to provide partial protection against Y. pestis infection (2, 3, 11, 30) . Three other proteins used in the challenge experiment in this study, YPO2092, YPO2109, and YPO2120, are encoded in the 33-kb chromosomal fragment that is absent from the biovar Microtus strain Y. pestis 201, which is avirulent in humans (43) . Therefore, the protective efficiencies of the remaining 24 proteins were evaluated using the adjuvant CpG1826-ODN, which stimulates mainly Th1 immunity in mice.
Mice immunized three times with 15 g protein-10 g CpG-ODN, 15 g LcrV-10 g CpG-ODN as a positive control, or PBS or 10 g CpG-ODN alone as a blank or negative control were subcutaneously challenged on the 60th day after the primary vaccination with 20ϫ or 200ϫ LD 50 of the Y. pestis 201 strain.
There were no survivors in the groups immunized with PBS and one survivor in the groups immunized with CpG-ODN, but the mice immunized with LcrV-CpG-ODN were fully protected against the same challenge dose. Besides LcrV, the other nine proteins ( Of the nine proteins which provide partial protection, YPO0606 (YapF) is a member of the autotransporter proteins, the family related to persistence and virulence in the host. One autotransporter protein, pertactin, was used previously as a vaccine against infection with Bordetella pertussis (18) . Recently, at least 10 putative autotransporters encoded in the genomes of Y. pestis have been identified, and four of them (YapC, YapE, YapN, and YapK) (25, 48) have been confirmed to contribute to cell adhesion and the virulence of the bacterium. YPO0612 and YPO1914 (YbtQ/Irp7) belong to the ABC transporter families involved in sugar and iron utilization, respectively. YbtQ is involved in iron acquisition in the early stage of bubonic plague and is associated with the virulence of Yersinia enterocolitica in mice. Both autotransporters and ABC transporters are targets for the development of antibacterial vaccines.
Molecular chaperones are the proteins required for the correct folding and secreting of the chaperoned protein. During bacterial infection, these proteins are immunodominant antigens that can stimulate T-and B-cell responses. Among the nine proteins, YPO3119 (HtpG) and YPCD1.05c (SycE) are molecular chaperones. HtpG is heat shock protein 90. SycE is the chaperone to YopE, a virulence factor of the T3SS which can deliver the fused heterologous antigens into the major histocompatibility complex class I-restricted antigen-processing pathway to induce a CD8 ϩ T-cell response (46) .
As molecular chaperones, lipoproteins are among the immunodominant antigens affecting both innate and adaptive immunity. Lipoprotein-based vaccines against microorganisms such as Neisseria meningitides, Mycobacterium tuberculosis, and Helicobacter pylori are under investigation (13, 22, 36) . Two lipoproteins, YPO0420 and YPO1377, were found to be T-cell antigens and provided protection against Y. pestis.
The other two proteins, YPO3047 and YPO3720, are predicted to be presented on the cell surface and extracellular space. Both of them have recently been demonstrated to be involved in pathogenesis in prokaryotes (4) .
Concluding remarks. The live, attenuated vaccine EV76 has historically been the most widely used vaccine against infection with Y. pestis. Vaccination with this strain induces protection against subcutaneous and inhalation challenges in murine models. Unfortunately, this attenuated vaccine strain can evoke adverse reactions in humans. Currently, the use of EV76 is banned in the United States and Europe. However, understanding the protective mechanism of this vaccine will help us to identify new potential vaccine targets for the development of more efficient subunit vaccines.
In our previous study, the humoral immune responses in rabbits repeatedly immunized with EV76 were screened by using a protein microarray containing 149 Y. pestis proteins, and antibodies to 50 proteins were detected (27) . There are 11 proteins besides F1 and LcrV antigens to which the predominant antibody response occurred.
IFN-␥ production is a primary indicator of T-cell activation. T-cell-mediated cellular immunity should play indispensable roles in fighting infection with Y. pestis through the production of cytokines IFN-␥ and tumor necrosis factor alpha. In this study, T-cell antigens identified by analyzing the genome of Y. pestis were first screened in mice immunized with EV76. Based on the results of the bioinformatics analysis and previous findings, 261 gene products were selected for testing of their abilities to induce T-cell responses, and 34 of them stimulated stronger IFN-␥ responses. Nine proteins (YPO0606, YPO1914, YPO0612, YPO3119, YPO3047, YPO1377, YPCD1.05c, YPO0420, and YPO3720) may provide partial protection against challenge with a low dose (20ϫ LD 50 ) of Y. pestis. Although these proteins cannot provide full protection, as can LcrV, the protective efficiency may be improved by changing the immunization schemes and combining the proteins with F1 and/or LcrV in vaccine research to improve protection against F1 Ϫ and/or LcrV mutant strains that are still virulent (35) . 
